This morning, Concordia announced it would buy Covis Pharma SARL and Covis Injectables SARL for (U.S.) $1.2-billion in cash. The company said it would finance the pickup through a combination of term loans, bonds and equity.
“Covis’s strong commercial momentum will have an immediate and material impact on our top- and bottom-line financial results,” said CEO Mark Thompson. “In the longer term, this transaction creates greater scale and diversification for Concordia, which should support the continued execution of our aggressive growth plans.”
Walewicz says this acquisition adds “substantially” to Concordia’s top and bottom line. Although he notes that all the operating metrics are not yet available, he estimates the deal was done at about 6x pro forma revenues. He points out that Covis’s gross margins are in the 90% range and the company adds no new headcount and has limited operating expenses.
The analyst says this deal will effectively double the size of Concordia.
“CXR expects its existing business to deliver US$40-43 million in revenue in the fourth quarter and the the Covis Assets to deliver approx. US$47-52 million in revenues in the same period,” he notes.
In a research update to clients this morning, Walewicz maintained his “Buy” rating on Concordia Healthcare and placed his target price, which was set at $48.00, under review.
Shares of Concordia Healthcare today closed up 25.2% to $80.34.
Nationwide’s chief market strategist Mark Hackett told CNBC’s Worldwide Exchange on Dec. 3 that survey data may look weak, but… [Read More]
Roth Capital Markets initiated coverage of Microbot Medical (Microbot Medical Stock Quote, Chart, News, Analysts, Financials NASDAQ:MBOT) with a “Buy”… [Read More]
Beacon Securities analyst Russell Stanley said Texas is “getting bigger for cannabis operators” after the state’s Department of Public Safety… [Read More]
RBC Dominion Securities analyst Darko Mihelic said Bank of Nova Scotia’s (Bank of Nova Scotia Stock Quote, Chart, News, Analysts,… [Read More]
Marvell Technology (Marvell Technology Stock Quote, Chart, News, Analysts, Financials NASDAQ:MRVL) reported largely in-line fiscal third-quarter results and offered longer-term… [Read More]
Beacon Securities analyst Russell Stanley maintained his “Buy” rating and C$5.00 price target on Curaleaf Holdings (Curaleaf Holdings Stock Quote,… [Read More]